Companies that have significant growth prospects for profitability and returns can add tangible upside to your portfolio. Oncimmune Holdings and APQ Global are examples of many potential outperformers that analysts are bullish on. I would suggest taking a look at my list of companies that compare favourably in all criteria, and consider whether they would add value to your current portfolio.

Oncimmune Holdings Plc (AIM:ONC)

Oncimmune Holdings Plc, an early cancer detection company, develops and commercializes products to diagnose cancer in the United Kingdom and North America. Formed in 2015, and now led by CEO Geoffrey Hamilton-Fairley, the company currently employs 47 people and with the stock’s market cap sitting at GBP £67.16M, it comes under the small-cap stocks category.

An outstanding 52.22% earnings growth is forecasted for ONC, driven by strong underlying sales growth over the next few years. An affirming signal is when net income increase is supported by top-line growth. Since net income isn’t artificially inflated by one-off initiatives such as cost-cutting, we know this profit growth is more likely to be sustainable. We see this bottom-line expansion directly benefiting shareholders, with expected return on equity coming in at a notable 23.74%. ONC’s bullish prospects on both the top and bottom lines make it an interesting stock to invest more time to understand how it can add value to your portfolio. Want to know more about ONC? Have a browse through its key fundamentals here.

APQ Global Limited (AIM:APQ)

APQ Global Limited, together with its subsidiary, APQ Partners LLP, operates as an asset management company in the Cayman Islands and Guernsey. APQ Global was formed in 2016 and with the company’s market cap sitting at GBP £79.23M, it falls under the small-cap stocks category.

Thinking of investing in APQ? Take a look at its other fundamentals here.

Medica Group PLC (LSE:MGP)

Medica Group PLC provides teleradiology reporting services to NHS trusts and other customers in the United Kingdom. Formed in 2013, and currently lead by John Graham, the company provides employment to 83 people and has a market cap of GBP £233.89M, putting it in the small-cap group.

MGP’s forecasted bottom line growth is an exceptional triple-digit, driven by the underlying double-digit sales growth of 47.51% over the next few years. Although reduction in cost is not the most sustainable operational activity, the expanding top-line growth, on the other hand, is encouraging. We see this bottom-line expansion directly benefiting shareholders, with expected return on equity coming in at a notable 29.85%. MGP’s impressive outlook on all aspects makes it a worthy company to spend more time to understand. Could this stock be your next pick? Have a browse through its key fundamentals here.